Navigation path

Pharmaceuticals - Community Register


Community register of orphan medicinal products


Product information

Sequence-modified recombinant human factor VIIa

EU orphan designation number: EU/3/09/676   
Active ingredient: Sequence-modified recombinant human factor VIIa
Indication: Treatment of haemophilia B
Sponsor: Bayer Pharma AG
Müllerstrasse 178, D-13342 Berlin, Deutschland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
12/10/2009 Orphan Designation EMEA/OD/062/09 (2009)7853 of 08/10/2009
21/10/2011 Change name of sponsor